|
Syncona Ltd - London-based investor in life science companies - Invests $24.5 million in ophthalmic gene therapy company Beacon Therapeutics’ $75 million Series C financing. Says the financing round was oversubscribed and brings Beacon’s total funding raised so far to approximately $367 million. Beacon will use the proceeds ‘to progress commercialisation plans’ and to complete the development of its lead programme laru-zova, ‘a potential best-in-class gene therapy’ for X-linked retinitis pigmentosa, Syncona says. Syncona’s holding value of Beacon will now be $237.6 million, including new capital invested, and it will hold a 38.4% ownership stake. Elisa Petris, managing partner at Syncona Investment Management Limited and director at Beacon, comments: ‘We are delighted that Beacon has attracted further external financing, underlining the progress the team has made and scale of the company’s ambition. Beacon has generated a differentiated set of data demonstrating the potentially transformational benefit of laru-zova for patients with devastating blinding conditions. We believe the combination of the clinical data generated and this further funding provides the company with a significant opportunity to lead its field.’ Current stock price: 98.60 pence, up 1.9% on Friday in London 12-month change: up 9.6% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
